

Product Data Sheet

L-NIO dihydrochloride

 Cat. No.:
 HY-100986

 CAS No.:
 159190-44-0

 Molecular Formula:
 C₇H₁₇Cl₂N₃O₂

 Molecular Weight:
 246.13

Target: NO Synthase

Pathway: Immunology/Inflammation

Storage: -20°C, stored under nitrogen, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from

moisture)

SOLVENT & SOLUBILITY

In Vitro

H₂O: 125 mg/mL (507.86 mM; Need ultrasonic) DMSO: 33.33 mg/mL (135.42 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.0629 mL	20.3145 mL	40.6289 mL
	5 mM	0.8126 mL	4.0629 mL	8.1258 mL
	10 mM	0.4063 mL	2.0314 mL	4.0629 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (406.29 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (10.16 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 2.5 mg/mL (10.16 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.16 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with K_is of 1.7,

3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively^{[1][2]}. L-NIO dihydrochloride induces a

consistent focal ischemic infarctin rats [2].

IC₅₀ & Target Ki: 1.7 μM (nNOS), 3.9 μM (eNOS), 3.9 μM (iNOS)^[1]

Page 1 of 2

In Vitro	neuronal (nNOS), endo	L-NIO is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with K _i s of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	MCE has not independe	L-NIO (2.0 µmol, 3 days post-ischemia) causes focal cerebral ischemia in the adult rat brain ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Adult male Sprague Dawley rats (250-350 g) ^[2]		
	Dosage:	0.04-2.0 μmol/(3.0-5.0 μL) per rat		
	Administration:	Injected into striatum 3 days post-ischemia		
	Result:	2.0 μmol L-NIO produced an infarct significantly different in volume from sham animals.		

CUSTOMER VALIDATION

• Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Babu BR, et al. N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase. J Biol Chem. 1998 Apr 10;273(15):8882-9.

[2]. Van Slooten AR, et al. L-NIO as a novel mechanism for inducing focal cerebral ischemia in the adult rat brain. J Neurosci Methods. 2015 Apr 30;245:44-57.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA